We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
30
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
1
3.3%
Completed
24
80.0%
Not yet recruiting
Recruiting
3
10.0%
Terminated
No approval data available
- An experimental malaria vaccine, PfSPZ Vaccine, demonstrated significant protection against parasite infection and clinical malaria for up to two years in healthy Malian adults. - The vaccine also showed promise in protecting women from malaria during pregnancy, with efficacy rates ranging from 49% to 86% in an exploratory analysis. - The trials, supported by the NIH, suggest that preconception immunization with PfSPZ Vaccine could be a new strategy to reduce mortality for women with malaria in pregnancy. - Further research is planned to assess the safety and efficacy of PfSPZ Vaccine administered during pregnancy in larger clinical trials.
